SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin

NCT01200797 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

19

Enrollment

NIH

Sponsor class

Stopped Slow accrual was the reason for study termination.

Conditions

Recurrent Fallopian Tube Cancer
Recurrent Ovarian Epithelial Cancer
Recurrent Primary Peritoneal Cavity Cancer

Interventions

DRUG: SJG-136
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)